CLINICAL AND SOCIODEMOGRAPHIC FEATURES OF HIV-INFECTED PATIENTS WITH IMMUNE RECONSTITUTION INFLAMMATORY SYNDROM, ANTIOQUIA – COLOMBIA

CARACTERIZACIÓN CLÍNICA Y SOCIODEMOGRÁFICA DE PACIENTES CON VIH CON SÍNDROME INFLAMATORIO DE RECONSTITUCIÓN INMUNE, ANTIOQUIA – COLOMBIA

Published 2022-09-06


https://doi.org/10.30554/archmed.22.1.4350.2022
Open | Download
PDF (Spanish) FLIP HTML (Spanish) XML (Spanish)
Issue
Vol. 22 No. 1 (2022): .
Section
Artículos de Investigación
How to Cite
Gallego-Quintero, S., Patiño-Isaza, A. M. ., Florez-Restrepo, D. L. ., Benjumea-Bedoya, D. ., Sanchez, I. P., Villegas-Arbeláez, E., Giraldo-Hoyos, S. ., Botero-Garcés, J. H., Taborda-Vanegas, N. A., & Alzate-Ángel, J. C. . (2022). CLINICAL AND SOCIODEMOGRAPHIC FEATURES OF HIV-INFECTED PATIENTS WITH IMMUNE RECONSTITUTION INFLAMMATORY SYNDROM, ANTIOQUIA – COLOMBIA. Archivos De Medicina , 22(1). https://doi.org/10.30554/archmed.22.1.4350.2022
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX
DOI

https://doi.org/10.30554/archmed.22.1.4350.2022
Dimensions
PlumX

How to Cite

Gallego-Quintero, S., Patiño-Isaza, A. M. ., Florez-Restrepo, D. L. ., Benjumea-Bedoya, D. ., Sanchez, I. P., Villegas-Arbeláez, E., Giraldo-Hoyos, S. ., Botero-Garcés, J. H., Taborda-Vanegas, N. A., & Alzate-Ángel, J. C. . (2022). CLINICAL AND SOCIODEMOGRAPHIC FEATURES OF HIV-INFECTED PATIENTS WITH IMMUNE RECONSTITUTION INFLAMMATORY SYNDROM, ANTIOQUIA – COLOMBIA. Archivos De Medicina , 22(1). https://doi.org/10.30554/archmed.22.1.4350.2022

Download Citation

license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Salomon Gallego-Quintero
Médico, Corporación Universitaria Remington. Medellín, Colombia
https://orcid.org/0000-0002-1609-2873 ORCID
Ana María Patiño-Isaza
Médico, Corporación Universitaria Remington. Medellín, Colombia
https://orcid.org/0000-0003-3586-7096 ORCID
Daniela Lucía Florez-Restrepo
Médico, Corporación Universitaria Remington. Medellín, Colombia
https://orcid.org/0000-0002-2382-2707 ORCID
Dione Benjumea-Bedoya
Docente Investigador, Corporación Universitaria Remington. Medellín, Colombia
https://orcid.org/0000-0002-4004-2219 ORCID
Isaura Pilar Sanchez
Docente Investigador, Corporación Universitaria Remington. Medellín, Colombia
https://orcid.org/0000-0002-1415-0785 ORCID
Esteban Villegas-Arbeláez
Médico de Servicio Social Obligatorio, Unidad de Investigación Clínica - Corporación para Investigaciones Biológicas, CIB. Medellín, Colombia
https://orcid.org/0000-0001-7025-5760 ORCID
Sofía Giraldo-Hoyos
Médico de Servicio Social Obligatorio, Unidad de Investigación Clínica - Corporación para Investigaciones Biológicas, CIB. Medellín, Colombia
https://orcid.org/0000-0001-7384-9599 ORCID
Jorge Humberto Botero-Garcés
Médico y Cirujano, MSc en Inmunología, Especialista en estadística. Grupo de Parasitología, Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad de Antioquia. Unidad de Investigación Clínica, Corporación para Investigaciones Biológicas-CIB. Medellín, Colombia
https://orcid.org/0000-0002-3478-0194 ORCID
Natalia Andrea Taborda-Vanegas
Docente Investigador, Corporación Universitaria Remington. Medellín, Colombia
https://orcid.org/0000-0001-6085-855X ORCID
Juan Carlos Alzate-Ángel
Coordinador Unidad de Investigación Clínica - Corporación para Investigaciones Biológicas, CIB. Medellín, Colombia
https://orcid.org/0000-0003-0319-0623 ORCID
Show authors biography

Background: Despite combined antiretroviral therapy effectiveness for the control of HIV infection, 15-30% of these patients develop Immune Reconstitution Inflammatory Syndrome (IRIS), consisting in a clinical worsening at the beginning of combined Antiretroviral Therapy (cART). It is important to know the prevalence and characteristics of people with IRIS to generate prevention strategies.

Objective: To describe the prevalence and sociodemographic characteristics of patients with IRIS HIV-related, from a health care facility in Antioquia - Colombia.

Methods: In a population of 515 patients that started cART between 2.013-2.018, we developed a cross-sectional study with a simple random sampling of 188 HIV patients. The presence of IRIS was defined according to French criteria or high suspected IRIS in those who had insufficient clinical information and have developed an opportunistic infection (OI) after cART initiation.

Results: The prevalence of IRIS was 12,8% (12,5% by French criteria and 87,5% by high suspected IRIS). IRIS patients were 25% women, median age 41,5 years. 87,5% presented OI. From these, the most common was tuberculosis disease (72,7%).

Conclusions: In the era of cART, there are still an important number of IRIS cases, which indicates the need to continue implementing preventive and diagnostic protocols and early treatment initiation.

Article visits 673 | PDF visits 322

Downloads

Download data is not yet available.
  1. Joint United Nations Program on HIV/AIDS (UNAIDS). UNAIDS data 2020. Unaids. Geneva, Switzerland; 2020.
  2. Cuenta de Alto Costo [CAC]. Situación del VIH/SIDA en Colombia 2020. Bogotá, Colombia; 2020.
  3. Angulo-Rodríguez YJ. En la infección por VIH, ¿es mejor prevenir que curar? . Medicas UIS. 2015;28(2):183–185.
  4. Ochoa R. VIH/SIDA y desarrollo. Revista Cubana de Hiegiene y Epidemiología. 2004 May;42(2).
  5. Programa Conjunto de las Naciones unidas sobre VIH/SIDA. Estrategia 90-90-90 Un ambicioso objetivo de
  6. tratamiento para contribuir al fin de la epidemia de sida. Onusida. 2013;39.
  7. Fondo Colombiano de Enfermedades de Alto Costo Cuenta de Alto Costo [CAC]. Situación del VIH Sida en
  8. Colombia. Bogotá, Colombia: Fondo Colombiano de Enfermedades de Alto Costo; 2018. 1–161 p.
  9. Maartens G, Celum C, Lewin SR. HIV infection: Epidemiology, pathogenesis, treatment, and prevention.
  10. Lancet. 2014;384:258–271. DOI: 10.1016/S0140-6736(14)60164-1
  11. Bernal F. Farmacología De Los Antirretrovirales. Rev Médica Clínica Las Condes. 2016;27(5):682–697.
  12. DOI: 10.1016/j.rmclc.2016.09.013
  13. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral Drugs for Treatment
  14. and Prevention of HIV Infection in Adults : 2018 Recommendations of the International Antiviral Society
  15. – USA Panel. J Am Med Assoc. 2019;320(4):379–396. DOI: 10.1001/jama.2018.8431.Antiretroviral
  16. Osorio J, Álvarez D, Barreto-Mora J, Casanova-Bermeo M, Vargas-Plazas H, Giraldo-Bahamon G, et al. Infecciones pulmonares en pacientes con VIH 20 años después de la terapia antirretroviral combinada. ¿qué
  17. ha cambiado? Infectio. 2016;20(3):180–189. DOI: 10.1016/j.infect.2015.08.002
  18. Zheng Y, Zhou H, He Y, Chen Z, He B, He M, et al. The Immune Pathogenesis of Immune Reconstitution
  19. Inflammatory Syndrome Associated with Highly Active Antiretroviral Therapy in AIDS. AIDS Res Hum
  20. Retroviruses. 2014;30(12):1197–1202. DOI: 10.1089/aid.2014.0106
  21. Hidrón A, González Á. Síndrome inflamatorio de reconstitución inmune en pacientes infectados con el
  22. virus de la inmunodeficiencia humana y afecciones fúngicas. Infectio. 2012;16(Supl 3):51–58.
  23. DOI: 10.1016/S0123-9392(12)70027-9
  24. Sereti I. Immune reconstruction inflammatory syndrome in HIV infection: beyond what meets the eye. Top
  25. Antivir Med. 2020;27(4):106–111.
  26. Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Incidence and Lethality of Immune Reconstitution Disease in HIV-Infected Patients Starting Antiretroviral Therapy: Systematic Review and MetaAnalysis. Lancet Infect Dis. 2010;10(4):251–261. DOI: 10.1016/S1473-3099(10)70026-8.Incidence
  27. Nelson AM, Manabe YC, Lucas SB. Immune Reconstitution Inflammatory Syndrome (IRIS): What pathologists
  28. should know. Semin Diagn Pathol. 2017;34(4):340–351.
  29. Ministerio de Salud y Protección Social. Guía de práctica clínica (GPC) basada en la evidencia científica para
  30. la atención de la infección por VIH / Sida en adolescentes (con 13 años de edad o más) y adultos. Ministerio
  31. de Salud y Protección Social; 2014. 499 p.
  32. French MA, Price P, Stone SF. Immune Restoration Disease after Antiretroviral Therapy. AIDS.
  33. ;18(12):1615–1627. DOI: 10.1097/01.aids.0000131375.21070.06
  34. Pelaez-Gil MC, Villalobos-Mora C, Mora-Hernandez G. Síndrome de Reconstitución Inmune. Med Leg Costa
  35. Rica. 2017;34(1):1-6.
  36. Ratnam I, Chiu C, Kandala N-B, Easterbrook PJ. Incidence and Risk Factors for Immune Reconstitution Inflammatory Syndrome in an Ethnically Diverse HIV Type 1-Infected Cohort. Clin Infect Dis. 2006
  37. Feb;42(3):418–427. DOI: 10.1086/499356
  38. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. Aids.
  39. ;19(4):399–406. DOI: 10.1097/01.aids.0000161769.06158.8a
  40. Rateni L, Lupo S, Palazzi J, Racca L, Ghersevich S. Assessing Endocrine and Immune Parameters in Human Immunodeficiency Virus-Infected Patients Before and After the Immune Reconstitution Inflammatory
  41. Syndrome. Arch Endocrinol Metab. 2018;62(1):64–71. DOI: 10.20945/2359-3997000000010
  42. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and
  43. preventing HIV infection: recommendations for a public health approach. Vol. 2, WHO Library. Geneva,
  44. Switzerland; 2016. 1–429 p. DOI: 10.1097/00022744-199706000-00003
  45. Stanton J, Remiarz A, Wright P. Starting Antiretroviral Therapy in Treatment-Naive Persons Living With HIV :
  46. Is as Soon as Possible Good Enough When “ Rapid Start ” is Clinically Feasible ?. J Assoc Nurses AIDS
  47. Care. 2019;30(3):255–258.
  48. Azzolini E, Furia G, Cambieri A, Ricciardi W, Volpe M, Poscia A. Quality improvement of medical records
  49. through internal auditing: A comparative analysis. J Prev Med Hyg. 2019;60(3):E250–E255.
  50. DOI: 10.15167/2421-4248/jpmh2019.60.3.1203

Information

Keywords

QR code

Sistema OJS 3.4.0.10 - Metabiblioteca |